Received by email:

File: VPUSA_20190102_NR_newBOD.docx

/

Vodis USA, Inc. Announces New Board of Directors.


Bellingham, WA., January 2, 2019 - Vodis USA, Inc. is pleased to announce the appointment of a new member, Roy Lentz, 
--->to its Board of Directors effective immediately. With this appointment, the Board of Directors now consists of Mr. Len
--->tz, David Otto, and Plamen Ovagemov.
Mr. Lentz is the President and CEO of Lentz & Associates, Inc., a full-service public accounting firm in Bellingham, W
--->A. He is a graduate of Western Washington University with a BA in Accounting and has over thirty years of experience w
--->orking with individuals and small businesses to provide accounting and tax preparation services as well as dispute res
--->olution with the Internal Revenue Service. Currently, he specializes in personal and small business accounting and tax
---> return preparation as well as international taxation issues for U.S. citizens abroad and for nonresidents of the U.S.
---> with U.S. income. 
Mr. Otto is the founding Managing Partner of Martin Davis, PLLC. He received his B.A. from Harvard University and his 
--->J.D. from Fordham University School of Law. Mr. Otto has over thirty years of experience in corporate finance, securit
--->ies, mergers & acquisitions, corporate governance, and capital markets, and he is also a General Partner of Reflective
---> Venture Partners, a blockchain technology fund. 
Mr. Ovagemov is the current President of Vodis USA in addition to his role on the Board of Directors. He has been with
---> Vodis USA since its founding, serving as the company's Treasurer. Mr. Ovagemov took on the additional role of Preside
--->nt earlier this year.
"We are excited to welcome Mr. Lentz onto the Vodis USA Board." said Mr. Ovagemov. "The experience and knowledge that 
--->he brings to our leadership team will be invaluable to the company as it moves forward."
About Vodis Pharmaceuticals Inc. 
Vodis is one of North America's foremost brand names in the medical and recreational marijuana business with operation
--->s in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competi
--->tion they have entered with their "VIP" brand. The Company, with facilities in British Columbia and Washington State, 
--->is also actively looking into expansion opportunities in other countries and throughout the United States. While Vodis
---> and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or ret
--->ail activities in the United States, it can license its brand, production and consulting services to approved Washingt
--->on State licence holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associate
--->d under the VIP brand meet or exceed Vodis-brand quality standards. 
For further information please contact: 
Ivan Miliovski, Chief Executive Officer  Vodis Pharmaceuticals Inc.  1-866-210-1420 Ext103 
-or- 
Soy Garipoglu, Investor Relations Vodis Pharmaceuticals Inc. 8788 River Road Delta, BC  V4G 1B4 Contact: 778-990-8985 
--->Email: investorrelations@vodis.ca  Web: www.vodis.ca 
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no
---> responsibility for the adequacy or accuracy hereof. 
This news release contains "forward-looking information" within the meaning of applicable securities laws including st
--->atements relating to the outlook of the business of the Company, the Company's intention to complete the private place
--->ment financing, the potential granting of a cultivation license by Health Canada, and planned expenditures for upgrade
--->s and other renovations at the Company's Delta, BC, and Washington facilities. Although the Company believes consideri
--->ng the experience of its officers and directors, current conditions and expected future developments and other factors
---> that have been considered appropriate, that the expectations reflected in this forward-looking information are reason
--->able, undue reliance should not be placed on them as the Company can give no assurance that they will prove to be corr
--->ect. Actual results and developments may differ materially from those contemplated by these statements, depending on, 
--->among other things, the risks that the private placement financing may not close for any reason (including the failure
---> to obtain the required approvals or clearances from regulatory authorities) or that the terms of the private placemen
--->t financing may differ from those that currently are contemplated. The statements in this news release are made as of 
--->the date of this release. 
The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forwa
--->rd-looking statements, whether as a result of new information, future events or otherwise, except as expressly require
--->d by applicable law.